Home >> Research Area >>Neuroscience>>COX>> Ampiroxicam

Ampiroxicam

CAS# 99464-64-9

Ampiroxicam

Catalog No. BCC4426----Order now to get a substantial discount!

Product Name & Size Price Stock
Ampiroxicam: 5mg $58 In Stock
Ampiroxicam: 10mg Please Inquire In Stock
Ampiroxicam: 20mg Please Inquire Please Inquire
Ampiroxicam: 50mg Please Inquire Please Inquire
Ampiroxicam: 100mg Please Inquire Please Inquire
Ampiroxicam: 200mg Please Inquire Please Inquire
Ampiroxicam: 500mg Please Inquire Please Inquire
Ampiroxicam: 1000mg Please Inquire Please Inquire
Related Products
  • Tezampanel

    Catalog No.:BCC1993
    CAS No.:154652-83-2
  • Noopept

    Catalog No.:BCC1804
    CAS No.:157115-85-0
  • LY450108

    Catalog No.:BCC1725
    CAS No.:376594-67-1
  • Perampanel

    Catalog No.:BCC1847
    CAS No.:380917-97-5
  • Aniracetam

    Catalog No.:BCC4219
    CAS No.:72432-10-1

Quality Control of Ampiroxicam

Number of papers citing our products

Chemical structure

Ampiroxicam

3D structure

Chemical Properties of Ampiroxicam

Cas No. 99464-64-9 SDF Download SDF
PubChem ID 2176 Appearance Powder
Formula C20H21N3O7S M.Wt 447.46
Type of Compound N/A Storage Desiccate at -20°C
Synonyms CP 65703
Solubility DMSO : 50 mg/mL (111.74 mM; Need ultrasonic)
Chemical Name ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl]oxy]ethyl carbonate
SMILES CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
Standard InChIKey LSNWBKACGXCGAJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Ampiroxicam

DescriptionAmpiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. Target: COX Ampiroxicam is a non-steroidal anti-inflammatory drug. It is a prodrug of piroxicam. Ampiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. Ampiroxicam inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. Ampiroxicam blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. Ampiroxicam (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats [1]. Ultraviolet-A (UVA)-irradiated 1% Ampiroxicam sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% Ampiroxicam and 1% thiosalicylate (TOS). Concentration of Ampiroxicam is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam [2].

References:
[1]. Carty, T.J., et al., Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions, 1993. 39(3-4): p. 157-65. [2]. Sasaki, T., et al., Antigenic characterization in ampiroxicam-induced photosensitivity using an in vivo model of contact hypersensitivity. J Dermatol Sci, 1999. 21(3): p. 170-5.

Ampiroxicam Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ampiroxicam Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ampiroxicam

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2348 mL 11.1742 mL 22.3484 mL 44.6967 mL 55.8709 mL
5 mM 0.447 mL 2.2348 mL 4.4697 mL 8.9393 mL 11.1742 mL
10 mM 0.2235 mL 1.1174 mL 2.2348 mL 4.4697 mL 5.5871 mL
50 mM 0.0447 mL 0.2235 mL 0.447 mL 0.8939 mL 1.1174 mL
100 mM 0.0223 mL 0.1117 mL 0.2235 mL 0.447 mL 0.5587 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Ampiroxicam

Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.

Featured Products
New Products
 

References on Ampiroxicam

Differential property of antigenic characterization between piroxicam and ampiroxicam in contact hypersensitivity.[Pubmed:10850378]

Res Commun Mol Pathol Pharmacol. 1999;105(1-2):147-54.

Piroxicam (PXM; a non-steroidal anti-inflammatory drug) has been reported to induce photosensitivity. In our previous report, however, ultraviolet-A (UVA)-irradiated or non-irradiated PXM did not induce any reactions in the in vivo model of contact hypersensitivity, while positive patch testing was shown by Ampiroxicam (APX; a prodrug of PXM). The purpose of the present study was to clarify the influence of protein on the antigenicity of PXM using this model. Animals sensitized by UVA-irradiated 1% APX showed positive patch testing (open application) in UVA-irradiated 1% APX, while they were negative in challenge by UVA-irradiated PXM with or without 5% human serum albumin (HSA). Although animals sensitized by 1% thiosalicylate (TOS), which is thought to be an active hapten of PXM, were cross-reacted with UVA-irradiated 1% APX, they failed to react with UVA-irradiated 1% PXM with or without HSA. On the other hand, intra-dermal testing (intra-dermal application) in UVA-irradiated 0.1% PXM with 5% HSA was positive in animals sensitized by UVA-irradiated 1% APX, while 5% HSA alone, 0.1% PXM with 5% HSA and UVA-irradiated 0.1% PXM did not induce any reactions under this condition. Furthermore, concentration of PXM in the presence of HSA was reduced by UVA-irradiation in a time dependent manner, while the degradation of PXM was not observed in the absence of HSA. Finally, PXM almost disappeared at 120 min after the initiation of UVA-irradiation. The degradation of PXM irradiated by UVA was dependent on the concentration of HSA at the range of 0 to 4%. Hence, these results suggest that the presence of protein is necessary for the induction of the antigenic activity of PXM and the antigenic characterization of PXM is different from that of APX in contact hypersensitivity.

Antigenic characterization in ampiroxicam-induced photosensitivity using an in vivo model of contact hypersensitivity.[Pubmed:10527378]

J Dermatol Sci. 1999 Nov;21(3):170-5.

Ampiroxicam (APX), a prodrug of piroxicam (PXM), has been reported to induce photosensitivity. Antigenic characterization of these photosensitivities, however, is still insufficient. The purpose of the present study was to elucidate further mechanism of photosenstivity induced by APX and PXM using an in vivo model of contact hypersensitivity in guinea pigs. Animals sensitized with ultraviolet-A (UVA)-irradiated 1% APX showed positive reaction in the patch testing to UVA-irradiated 1% APX and 1% thiosalicylate (TOS), while they were negative in challenge with UVA-irradiated 1% PXM, non-irradiated APX and PXM, whereas none of UVA-irradiated or non-irradiated APX and PXM showed positive patch test reaction in animals sensitized with UVA-irradiated 1% PXM or control vehicles. Animals sensitized with 1% TOS were successfully challenged by 1% TOS and cross-reacted with UVA-irradiated 1% APX; however, they failed to react with UVA-irradiated PXM, non-irradiated APX and PXM. Indeed, the in vitro study revealed that the concentration of APX was easily reduced by the increase of UVA irradiation dose, as compared with that of PXM. Interestingly, absorption spectrum of UVA-irradiated APX was similar to that of TOS, which is thought to be an active hapten of PXM. In the present study, we succeeded in the development of a novel animal model reflecting the clinical observations. Furthermore, these results suggested that contact hypersensitivity induced by UVA-irradiated APX is developed by photoproducts of APX itself, but not by the biotransformation of APX to PXM.

Preoperative ampiroxicam reduces postoperative pain after hand surgery.[Pubmed:11469844]

J Hand Surg Br. 2001 Aug;26(4):377-9.

We performed a double blind randomised controlled study to assess whether the preoperative administration of Ampiroxicam reduced the level of postoperative pain in 120 patients who underwent surgery to a hand under brachial plexus block. We found that preoperative (pre-emptive) administration of Ampiroxicam significantly reduced the postoperative pain levels and the need for postoperative analgesia.

Description

Ampiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.

Keywords:

Ampiroxicam,99464-64-9,CP 65703,Natural Products,COX, buy Ampiroxicam , Ampiroxicam supplier , purchase Ampiroxicam , Ampiroxicam cost , Ampiroxicam manufacturer , order Ampiroxicam , high purity Ampiroxicam

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: